Company / Operating Cash Flow per Share
PharmaCyte Biotech, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.27
FY2025
5-year range
-$2.14 / -$0.20
FY2021-FY2025
Trend
-18.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-2.14 in FY2021 to $-0.00 in FY2016.
Based on SEC 10-K filings.
-0.27 in FY2025.
Declined from $-0.20 to $-0.27 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 18.5% year-over-year.
- Peak operating cash flow per share was recorded in FY2016.
- Lowest operating cash flow per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.27 | -18.5% |
| FY2024 | -$0.23 | -13.7% |
| FY2023 | -$0.20 | +90.5% |
| FY2022 | -$2.09 | +2.1% |
| FY2021 | -$2.14 | -88112.7% |
| FY2020 | -$0.00 | +51.6% |
| FY2019 | -$0.01 | -35.9% |
| FY2018 | -$0.00 | +33.7% |
| FY2017 | -$0.01 | -162.2% |
| FY2016 | -$0.00 | -275.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026